It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Purpose
To identify parameters to predict upgrading in biopsy Grade Group (GG) 2 prostate cancer patients without cribriform and intraductal carcinoma (CR/IDC) on biopsy.
Methods
Preoperative biopsies from 657 men undergoing radical prostatectomy (RP) for prostate cancer were reviewed for GG, presence of CR/IDC, percentage Gleason pattern 4, and tumor length. In men with biopsy GG2 without CR/IDC (n = 196), clinicopathologic features were compared between those with GG1 or GG2 without CR/IDC on RP (GG ≤ 2−) and those with GG2 with CR/IDC or any GG > 2 (GG ≥ 2+). Logistic regression analysis was used to predict upgrading in the biopsy cohort.
Results
In total 283 men had biopsy GG2 of whom 87 (30.7%) had CR/IDC and 196 (69.3%) did not. CR/IDC status in matched biopsy and RP specimens was concordant in 179 (63.3%) and discordant in 79 (27.9%) cases (sensitivity 45.1%; specificity 92.6%). Of 196 biopsy GG2 men without CR/IDC, 106 (54.1%) had GG ≥ 2+ on RP. Multivariable logistic regression analysis showed that age [odds ratio (OR): 1.85, 95% confidence interval (CI)1.09–3.20; p = 0.025], percentage Gleason pattern 4 (OR 1.54, 95% CI 1.17–2.07; p = 0.003), PI-RADS 5 lesion (OR 2.17, 95% CI 1.03–4.70; p = 0.045) and clinical stage T3 (OR 3.60; 95% CI 1.08–14.50; p = 0.049) were independent parameters to predict upgrading to GG ≥ 2+ on RP in these men.
Conclusions
Age, clinical stage T3, percentage Gleason pattern 4 and presence of PI-RADS 5 lesions are independent predictors for upgrading in men with biopsy GG2 without CR/IDC. These findings allow for improved clinical decision-making on surveillance eligibility in intermediate-risk prostate cancer patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Anser Prostate Operation Clinic, Rotterdam, The Netherlands; Maasstad Hospital, Department of Pathology, Rotterdam, The Netherlands (GRID:grid.416213.3) (ISNI:0000 0004 0460 0556); Maasstad Hospital, Department of Urology, Rotterdam, The Netherlands (GRID:grid.416213.3) (ISNI:0000 0004 0460 0556)
2 University Medical Centre, Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X); University Medical Centre, Department of Radiology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
3 Anser Prostate Operation Clinic, Rotterdam, The Netherlands (GRID:grid.5645.2); Maasstad Hospital, Department of Pathology, Rotterdam, The Netherlands (GRID:grid.416213.3) (ISNI:0000 0004 0460 0556)
4 Anser Prostate Operation Clinic, Rotterdam, The Netherlands (GRID:grid.416213.3); Maasstad Hospital, Department of Pathology, Rotterdam, The Netherlands (GRID:grid.416213.3) (ISNI:0000 0004 0460 0556)
5 Anser Prostate Operation Clinic, Rotterdam, The Netherlands (GRID:grid.416213.3); University Medical Centre, Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
6 Anser Prostate Operation Clinic, Rotterdam, The Netherlands (GRID:grid.5645.2); Maasstad Hospital, Department of Urology, Rotterdam, The Netherlands (GRID:grid.416213.3) (ISNI:0000 0004 0460 0556)
7 Anser Prostate Operation Clinic, Rotterdam, The Netherlands (GRID:grid.416213.3); Maasstad Hospital, Department of Urology, Rotterdam, The Netherlands (GRID:grid.416213.3) (ISNI:0000 0004 0460 0556)
8 Anser Prostate Operation Clinic, Rotterdam, The Netherlands (GRID:grid.416213.3); Franciscus Gasthuis & Vlietland, Department of Urology, Rotterdam, The Netherlands (GRID:grid.461048.f) (ISNI:0000 0004 0459 9858)
9 University Medical Centre, Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)